Herbal Supplements for Prostate Enlargement: Current State of the Evidence

Published:October 26, 2017DOI:


      To provide a comprehensive review of the current state of herbal supplement market for lower urinary tract symptoms (LUTS) and correlate the ingredients of each product with available scientific evidence.

      Materials and Methods

      Twenty-seven products from that were advertised as herbal supplements for LUTS and had listed their active ingredients were selected. Active ingredients were reviewed on Google Scholar. Product price, warranty, and consumer review information were also collected.


      A total of 58 unique active ingredients were identified. The mean number of ingredients was 8.26 (standard deviation 5.25). Whereas 17 (63%) products had an ingredient with a systematic review to support their use, 20 (74%) had an ingredient with conflicting evidence based on systematic reviews. Out of the supplements that contained ingredients supported by literature, all (100%) products simultaneously had other ingredients with no, conflicting, or refuting evidence. There was no (0%) product that contained only scientifically proven ingredients. There is no scientific study to evaluate these supplements as a whole.


      Despite the widespread use of herbal supplements for LUTS, there is scant scientific evidence to support their safety and efficacy. Lack of adequate regulation and government support for research and development are some of the factors that disincentivize researchers to study safety and efficacy of these products. We encourage physicians to warn their patients on the lack of adequate evidence to support the safety and efficacy of many of these supplements.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Eisenberg D.M.
        • Davis R.B.
        • Ettner S.L.
        • et al.
        Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey.
        JAMA. 1998; 280: 1569-1575
        • Schultz A.M.
        • Chao S.M.
        • McGinnis J.M.
        Integrative Medicine and the Health of the Public: A Summary of the February 2009 Summit.
        National Academies Press, Washington, DC2009
        • Shultz M.
        Comparing test searches in PubMed and Google Scholar.
        J Med Libr Assoc. 2007; 95: 442-445
        • Posadzki P.
        • Watson L.K.
        • Ernst E.
        Adverse effects of herbal medicines: an overview of systematic reviews.
        Clin Med (Lond). 2013; 13 (PMID): 7-12
      1. Cease and desist notification issued by State of New York Office of the Attorney General.
        (Available at:)
        • Morris C.A.
        • Avorn J.
        Internet marketing of herbal products.
        JAMA. 2003; 290: 1505-1509
        • Frommenwiler D.A.
        • Sudberg S.
        • Sharaf M.
        • Bzhelyansky A.
        • Lucas B.
        • Reich E.
        Adulteration of St. John's wort products: how to identify quality problems.
        Planta Med. 2016; 81: S1-S381
        • Calixto J.B.
        Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents).
        Braz J Med Biol Res. 2000; 33 (PMID): 179-189
        • Organization, World Health, and Others
        WHO Guidelines on safety monitoring of herbal medicines in pharmacovigilance systems.
        World Health Organization, Geneva2004 (Available at:)
        • Bailey R.L.
        • Gahche J.J.
        • Miller P.E.
        • Thomas P.R.
        • Dwyer J.T.
        • Why U.S.
        Adults use dietary supplements.
        JAMA Intern Med. 2013; 173: 355-361
        • Marks L.S.
        • Partin A.W.
        • Epstein J.I.
        • et al.
        Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.
        J Urol. 2000; 163: 1451-1456
        • Gerber G.S.
        • Kuznetsov D.
        • Johnson B.C.
        • Burstein J.D.
        Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms.
        Urology. 2001; 58 (discussion 964-65): 960-964
        • Bent S.
        • Kane C.
        • Shinohara K.
        • et al.
        Saw palmetto for benign prostatic hyperplasia.
        N Engl J Med. 2006; 354: 557-566
        • Wilt T.J.
        • Ishani A.
        • Stark G.
        • MacDonald R.
        • Lau J.
        • Mulrow C.
        Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.
        JAMA. 1998; 280: 1604-1609
        • Tacklind J.
        • Macdonald R.
        • Rutks I.
        • Stanke J.U.
        • Wilt T.J.
        Serenoa repens for benign prostatic hyperplasia.
        Cochrane Database Syst Rev. 2012; (CD001423)
        • Agbabiaka T.B.
        • Pittler M.H.
        • Wider B.
        • et al.
        Serenoa repens (saw palmetto): a systematic review of adverse events.
        Drug Saf. 2009; 32: 637-647
        • Nguyen T.
        • Garg A.
        The potential of increased bleeding rates in geriatrics who takes saw palmetto, an herbal supplement, in concurrence with blood thinners.
        J Am Med Dir Assoc. 2017; 18: B24-B25
        • Dunzendorfer U.
        • Drahovsky D.
        C-peptide, testosterone, estrogen, cortisol and zinc in patients with benign hyperplasia of the prostate.
        Urol Int. 1980; 35: 369-374
        • Zaichick V.
        • Sviridova T.V.
        • Zaichick S.V.
        Zinc in the human prostate gland: normal, hyperplastic and cancerous.
        Int Urol Nephrol. 1997; 29: 565-574
        • Willden E.G.
        • Robinson M.R.G.
        Plasma zinc levels in prostatic disease.
        Br J Urol. 1975; 47 (Blackwell Publishing Ltd): 295-299
        • Lagiou P.
        • Wuu J.
        • Trichopoulou A.
        • Hsieh C.C.
        • Adami H.O.
        • Trichopoulos D.
        Diet and benign prostatic hyperplasia: a study in Greece.
        Urology. 1999; 54: 284-290
        • Kristal A.R.
        • Arnold K.B.
        • Schenk J.M.
        • et al.
        Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
        Am J Epidemiol. 2008; 167: 925-934
        • Schwarz S.
        • Obermüller-Jevic U.C.
        • Hellmis E.
        • Koch W.
        • Jacobi G.
        • Biesalski H.-K.
        Lycopene inhibits disease progression in patients with benign prostate hyperplasia.
        J Nutr. 2008; 138: 49-53
        • Wilt T.J.
        • MacDonald R.
        • Ishani A.
        Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review.
        BJU Int. 1999; 83: 976-983
        • Ishani A.
        • MacDonald R.
        • Nelson D.
        • Rutks I.
        • Wilt T.J.
        Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis.
        Am J Med. 2000; 109: 654-664
        • Nahata A.
        • Dixit V.K.
        Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats.
        Andrologia. 2012; 44: 396-409
        • Safarinejad M.R.
        Stinging nettle for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study.
        J Herb Pharmacother. 2005; 5: 1-11